Evidence map›Paper›PMID 40865880›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention.

Thy Le, Isabella C Young, Jasmine L King, Mackenzie L Cottrell, Amar Shankar Kumbhar, Craig Sykes, Amanda Schauer, Gabriela De la Cruz, Caleb T Kozuszek, Nanditha Chundayil Kalathil and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Thy LeLampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Isabella C YoungDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jasmine L KingLampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mackenzie L CottrellDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Amar Shankar KumbharDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Craig SykesDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Amanda SchauerDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gabriela De la CruzLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Caleb T KozuszekDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nanditha Chundayil KalathilLampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandra AbelLampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rani S SellersDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Angela D M KashubaDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
S Rahima BenhabbourLampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: benhabs@email.unc.edu.

Funding

Ultra-Long-Acting Polymeric Injectable Multi-Purpose Prevention Technology for Contraception and HIV PreventionR01AI162246 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENHABBOUR, SOUMYA RAHIMA · 2021 to 2025
$3.7M
Ultra-long-acting Biodegradable and Tunable Polymeric Solid Implant for HIV Treatment MaintenanceR01AI176949 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Soumya Rahima Benhabbour, Mackenzie Cottrell · 2023 to 2026
$2.9M
NIAID NIH HHS R01 AI162246NIAID NIH HHS R01 AI176949
6 · The paper itself

Abstract

HIV is a global health issue affecting approximately 40 million people worldwide, with low patient adherence being the primary challenge for maintaining effective pre-exposure prophylaxis (PrEP). Limitations of oral PrEP are mainly attributed to lack of adherence due to pill fatigue or stigma [1, 2]. Recently introduced long-acting injectables offer several advantages over daily PrEP, namely by improving adherence and improving efficacy [3-5]. The approved long-acting injectable Apretude® is administered every two months and elicits a long pharmacokinetic tail of >15 months that can lead to potential drug-resistant virus [6]. To address these limitations, we report on an ultra-long-acting injectable cabotegravir/barium sulfate (CAB/BaSO₄) in-situ forming implant (ISFI) capable of maintaining therapeutic CAB concentrations (> 4× PA-IC

Indexed as

Anti-HIV AgentsHIV InfectionsPyridonesAbsorbable ImplantsAnimalsDelayed-Action PreparationsDiketopiperazinesDrug ImplantsFemaleHumansMaleMiceMice, Inbred BALB CPre-Exposure ProphylaxisTissue DistributionAnti-HIV AgentscabotegravirDelayed-Action PreparationsDiketopiperazinesDrug ImplantsPyridonesCabotegravirHIV preventionInjectableIn-situ forming implantsUltra-long-actingX-ray imaging

Identifiers

PMID40865880
PMCPMC12477885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.